Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Active, not recruiting · NCT06655896 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, skin disorder, systemic sclerosis | Active, not recruiting | Phase 2 | 2026-09-02 | NCT06655896 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
13 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Avera Cancer | Sioux Falls | United States | 4 |
| Boston Medical Center | Boston | United States | 200 |
| FL Medical Clinic Orlando Health | Zephyrhills | United States | 3 |
| James Cancer Hospital | Columbus | United States | 2 |
| LDS Hospital | Salt Lake City | United States | 82 |
| Michigan Med University of Michigan | Ann Arbor | United States | 2 |
| Northwestern University | Chicago | United States | 727 |
| Oregon Health Sciences University | Portland | United States | 33 |
| Sutter Health Network | San Pablo | United States | 2 |
| UCLA | Los Angeles | United States | 80 |
| UCSF | San Francisco | United States | 12 |
| University of Iowa | Iowa City | United States | 284 |
| University of Minnesota | Minneapolis | United States | 325 |